A Phase II, Randomized Study to Assess the Pharmacokinetics, Safety and Pharmacodynamics of Single and Repeat Doses of RPL554 Administered by Dry Powdered Inhaler in Patients With COPD
Phase of Trial: Phase II
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs Ensifentrine (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Verona Pharma
- 05 Nov 2019 According to a Ligand Pharmaceuticals media release, data from this trial were presented at the European Respiratory Society International Congress.
- 19 Sep 2019 According to a Verona Pharma media release, the postive interim data from this study will be presented at the European Respiratory Society (ERS) International Congress on Sunday, September 29, 2019 at 10:15 AM.
- 05 Aug 2019 Positive results from second part of the study published in the Verona Pharma Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History